3.055
Schlusskurs vom Vortag:
$3.19
Offen:
$3.2
24-Stunden-Volumen:
788.58K
Relative Volume:
0.28
Marktkapitalisierung:
$294.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.68M
KGV:
-1.8404
EPS:
-1.66
Netto-Cashflow:
$-54.24M
1W Leistung:
-3.60%
1M Leistung:
+9.14%
6M Leistung:
+66.08%
1J Leistung:
+71.68%
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
CABA
Cabaletta Bio Inc
|
3.055 | 307.09M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.84 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.46 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.22 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Cabaletta Bio (CABA) upgraded to buy: Here's what you should know - MSN
Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference - MarketBeat
Day Trade: What are Cabaletta Bio Inc.’s recent SEC filings showingJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - baoquankhu1.vn
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday - MarketBeat
CABA SEC FilingsCabaletta Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Are healthcare stocks underperforming Biodesix (BDSX) so far this year? - Bitget
Are Medical Stocks Lagging Biodesix (BDSX) This Year? - Yahoo Finance
Cabaletta Bio (CABA) grants 225,000 stock options to its president - Stock Titan
Cabaletta Bio (CABA) CEO awarded 674,000-share stock option grant - Stock Titan
TD Cowen Health Care Conference - marketscreener.com
Gains Report: Can Cabaletta Bio Inc deliver consistent dividendsJuly 2025 Analyst Calls & Fast Gain Swing Alerts - baoquankhu1.vn
CABA Should I Buy - Intellectia AI
CABA Technical Analysis & ETF Price Forecast - Intellectia AI
Here’s why Jacob Funds established a position in Cabaletta Bio (CABA) - MSN
Millennium Management LLC's Strategic Acquisition of Cabaletta B - GuruFocus
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Short Covering: Will Cabaletta Bio Inc announce a stock split2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
Aug EndMonth: What drives SATLWs stock price2025 Market Sentiment & Stock Market Timing Techniques - baoquankhu1.vn
Dividend Watch: Is PECO stock a falling knife or bargain buyRisk Management & Growth Oriented Trade Recommendations - baoquankhu1.vn
CABA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Market Rankings: Is Cabaletta Bio Inc stock trending bullishJuly 2025 Analyst Calls & High Accuracy Swing Trade Signals - baoquankhu1.vn
Millennium Group (CABA) jointly reports 5.3% holding of 5.13M shares - Stock Titan
Aug Shorts: Does Cabaletta Bio Inc have strong EBITDA marginsJuly 2025 Update & Accurate Buy Signal Notifications - baoquankhu1.vn
Here’s Why Jacob Funds Established a Position in Cabaletta Bio (CABA) - Insider Monkey
Alyeska group reports 4.67% Cabaletta Bio (CABA) stake via 4.5M warrants - Stock Titan
What are Cabaletta Bio Inc.’s recent SEC filings showingPortfolio Update Summary & Daily Risk Controlled Trade Plans - mfd.ru
CABA News & Events - Intellectia AI
Best Swing Trade Stocks Right Now • Updated Daily - Benzinga
Pharma News: Why retail investors favor Cabaletta Bio Inc. stock2025 Historical Comparison & Fast Entry High Yield Tips - mfd.ru
Cabaletta Bio Kicks Off Pivotal Myositis Trial, Touts Automated CAR-T Manufacturing Path to 2027 BLA - MarketBeat
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? - Nasdaq
Aug Drivers: Is Cabaletta Bio Inc stock a smart retirement pickJuly 2025 Recap & Fast Moving Market Watchlists - baoquankhu1.vn
CABA News Today | Why did Cabaletta Bio stock go up today? - MarketBeat
Cabaletta Bio Takes Spotlight at Guggenheim Summit as Autoimmune Bet Advances - MyChesCo
Cabaletta Bio shares climb after insider purchases - MSN
Update Recap: Is Cabaletta Bio Inc stock overvalued or fairly priced2025 Macro Impact & AI Powered Market Entry Strategies - baoquankhu1.vn
Trend Review: Is Cabaletta Bio Inc stock overvalued or fairly pricedJuly 2025 Technicals & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Globe and Mail
Cabaletta Bio to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Risk Off: What is Cabaletta Bio Incs P E ratio telling usJuly 2025 PostEarnings & Weekly High Return Stock Forecasts - baoquankhu1.vn
Swing Trade: Can Cabaletta Bio Inc deliver consistent dividendsQuarterly Earnings Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
US Market Wrap: Can Cabaletta Bio Inc disrupt its industryJuly 2025 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Highs Report: Will Tucows Inc outperform its industry peersMarket Activity Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
What makes Cabaletta Bio, Inc. (CABA) a strong momentum stock: Buy now? - MSN
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cabaletta Bio Inc-Aktie (CABA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | President, Science & Tech. |
Jan 21 '26 |
Buy |
2.19 |
11,312 |
24,763 |
31,312 |
| Tomasello Shawn | Director |
Jan 21 '26 |
Buy |
2.21 |
22,725 |
50,322 |
22,725 |
| Gavel Steve | Chief Commercial Officer |
Jan 21 '26 |
Buy |
2.27 |
22,170 |
50,215 |
22,170 |
| Bollard Catherine | Director |
Jan 21 '26 |
Buy |
2.27 |
4,405 |
9,982 |
5,405 |
| Nichtberger Steven | President & CEO |
Jan 21 '26 |
Buy |
2.24 |
45,000 |
100,778 |
1,031,483 |
| Simon Mark | Director |
Jan 21 '26 |
Buy |
2.28 |
11,061 |
25,261 |
147,205 |
| Gerard Michael | General Counsel |
Jan 21 '26 |
Buy |
2.27 |
6,600 |
14,979 |
6,600 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):